GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Asset Turnover

Albany Molecular Research (Albany Molecular Research) Asset Turnover : 0.14 (As of Jun. 2017)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Albany Molecular Research's Revenue for the three months ended in Jun. 2017 was $172.9 Mil. Albany Molecular Research's Total Assets for the quarter that ended in Jun. 2017 was $1,203.0 Mil. Therefore, Albany Molecular Research's Asset Turnover for the quarter that ended in Jun. 2017 was 0.14.

Asset Turnover is linked to ROE % through Du Pont Formula. Albany Molecular Research's annualized ROE % for the quarter that ended in Jun. 2017 was -13.36%. It is also linked to ROA % through Du Pont Formula. Albany Molecular Research's annualized ROA % for the quarter that ended in Jun. 2017 was -3.41%.


Albany Molecular Research Asset Turnover Historical Data

The historical data trend for Albany Molecular Research's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Asset Turnover Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.70 0.58 0.58 0.55

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.16 0.14 0.14

Competitive Comparison of Albany Molecular Research's Asset Turnover

For the Biotechnology subindustry, Albany Molecular Research's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albany Molecular Research's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albany Molecular Research's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Albany Molecular Research's Asset Turnover falls into.



Albany Molecular Research Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Albany Molecular Research's Asset Turnover for the fiscal year that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=570.45/( (865.567+1209.648)/ 2 )
=570.45/1037.6075
=0.55

Albany Molecular Research's Asset Turnover for the quarter that ended in Jun. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2017 )/( (Total Assets (Q: Mar. 2017 )+Total Assets (Q: Jun. 2017 ))/ count )
=172.932/( (1163.529+1242.374)/ 2 )
=172.932/1202.9515
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Albany Molecular Research  (NAS:AMRI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Albany Molecular Research's annulized ROE % for the quarter that ended in Jun. 2017 is

ROE %**(Q: Jun. 2017 )
=Net Income/Total Stockholders Equity
=-40.988/306.911
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-40.988 / 691.728)*(691.728 / 1202.9515)*(1202.9515/ 306.911)
=Net Margin %*Asset Turnover*Equity Multiplier
=-5.93 %*0.575*3.9195
=ROA %*Equity Multiplier
=-3.41 %*3.9195
=-13.36 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Albany Molecular Research's annulized ROA % for the quarter that ended in Jun. 2017 is

ROA %(Q: Jun. 2017 )
=Net Income/Total Assets
=-40.988/1202.9515
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-40.988 / 691.728)*(691.728 / 1202.9515)
=Net Margin %*Asset Turnover
=-5.93 %*0.575
=-3.41 %

Note: The Net Income data used here is four times the quarterly (Jun. 2017) net income data. The Revenue data used here is four times the quarterly (Jun. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Albany Molecular Research Asset Turnover Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines